Abstract
Local and centrally measured plasma HIV RNA (pVL) were assessed for agreement in two trials, ENCORE1 and SECOND-LINE. The proportion less than 200 copies/ml at week 48 was qualitatively similar [ENCORE1 2.5% (95% confidence interval, 95% CI-1.6 to 6.6); 1.9% (95% CI-1.9 to 2.1); SECOND-LINE 0.3% (95% CI-6.4 to 10.0); 1.8% (95% CI-4.7 to 8.3)]. The mean difference in log10 pVL copies/ml at weeks 0 and 48 was less than 0.2 log10 copies/ml in both trials. Our data indicate that central testing of pVL in HIV therapeutic trials is not warranted.
Original language | English |
---|---|
Pages (from-to) | 2480-2483 |
Number of pages | 4 |
Journal | AIDS |
Volume | 28 |
Issue number | 16 |
DOIs | |
Publication status | Published - 23 Oct 2014 |
Externally published | Yes |